Investor Presentaiton

2 Do I still have cancer? Has my cancer returned? GUARDANTREVEAL Cancer type Clinically relevant Minimal Residual Disease (MRD) detection capability for tissue-free assay achieved by epigenomics at high specificity (>98%) GUARDANT™ CRC RD Lung Breast INVESTOR 20 DAY 23 Tumor Fraction Level for Reliable Detection1 at the most challenging input level of 5ng 0.01% 0.01% 0.015% Typical cfDNA amounts in early stage clinically relevant samples² Above 5ng >95% samples Above 30ng <20% samples Above 60ng < 5%samples 1. Reliable detection was established as 95% limit of detection using titrations of clinical samples and cell lines for an assay at MRD-relevant 98% specificity and the most challenging and clinically relevant input amount. 2. Derived from internal data 34

View entire presentation